Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.
Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.
Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%). Aaron Cowen is reported with shared beneficial ownership of 5,674,778 shares (7.7%). The schedule states these securities are directly owned by advisory clients of Suvretta and includes a joint filing agreement and control-person identification.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share. The sale on April 6, 2026 was made under a pre-arranged Rule 10b5-1 trading plan.
Following this transaction, Nolan directly holds 340,106 shares of Lexeo common stock, which includes 261,349 Restricted Stock Units that may convert into shares if vesting conditions are satisfied.
Lexeo Therapeutics files its annual report detailing a clinical-stage genetic medicine pipeline focused on cardiovascular and neurodegenerative diseases. The company is advancing AAVrh10-based gene therapies, led by LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2‑arrhythmogenic cardiomyopathy.
Interim Phase 1/2 data for LX2006 show increased cardiac frataxin expression and meaningful improvements in cardiac structure, biomarkers and neurologic function, supported by multiple FDA designations and alignment on a registrational SUNRISE‑FA 2 study. LX2020 has demonstrated dose‑dependent PKP2 protein restoration and reduced arrhythmia burden in PKP2‑ACM patients. As of June 30, 2025, non‑affiliate equity market value was approximately $216.5 million, and 74,087,063 common shares were outstanding as of March 27, 2026.
Lexeo Therapeutics reported fourth quarter and full year 2025 results and detailed progress across its cardiac gene therapy pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $246.6 million, which it believes will fund operations into 2028.
For 2025, research and development expenses were $63.8 million, down from $74.1 million in 2024, while general and administrative expenses rose to $45.5 million from $31.7 million, reflecting growth investments. Net loss for 2025 was $100.0 million, or $1.86 per share, broadly similar to 2024.
Operationally, Lexeo advanced lead programs LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2 arrhythmogenic cardiomyopathy, including positive interim data, FDA alignment on the SUNRISE‑FA 2 pivotal trial design, and preparation for a Biologic License Application for LX2006. The company also highlighted a research collaboration with Johnson & Johnson on targeted cardiac delivery of AAV gene therapy and a previously executed $154 million equity financing to support its expanding cardiovascular pipeline.
Lexeo Therapeutics Inc ownership disclosure: The Vanguard Group filed an amended Schedule 13G/A reporting 0 shares beneficially owned and 0% of Lexeo Therapeutics common stock as of the filing. The amendment notes an internal realignment on January 12, 2026 and states certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538.
Lexeo Therapeutics Chief Executive Officer Richard Nolan Townsend acquired 2,623 shares of common stock at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c) and 16b-3(d). Following this award, he directly holds 395,106 shares, including 261,349 restricted stock units.
Lexeo Therapeutics, Inc. Chief Operating Officer Jose Manuel Otero acquired 5,930 shares of common stock on March 13, 2026 at $2.644 per share through the company’s 2023 Employee Stock Purchase Plan. After this transaction, he holds 131,390 shares in total, including 104,216 restricted stock units, in a transaction exempt under Rule 16b-3(c) and 16b-3(d).
Lexeo Therapeutics Chief Operating Officer Jose Manuel Otero reported an open-market sale of 3,016 shares of common stock on February 18, 2026 at a weighted average price of $6.3972 per share. The sale was made to cover tax obligations on the release of restricted stock units. After this transaction, Otero beneficially owned 125,460 shares, including 104,216 restricted stock units.